In September, BioNTech gears up for groundbreaking trials of mRNA-based cancer vaccine in the UK, diverging from its successful COVID-19 formula.

Buzz

Ngày cập nhật gần nhất: 1/5/2026

By 2030, BioNTech and the UK government anticipate treating approximately 10 thousand cancer patients with this groundbreaking vaccine technology.

Learn more:

For volunteers who have previously battled cancer and undergone treatment, BioNTech envisions that the mRNA vaccine will help prevent cancer cells from recurring. Clinical trials will determine the efficacy of shrinking tumors using the mRNA vaccine for patients in later stages. In both scenarios, volunteers will need to receive multiple doses of the vaccine rather than a single shot.

mRNA technology holds immense promise, yet the production cost of a single vaccine dose is not negligible. Some predictions suggest that by 2035, the mRNA vaccine market will reach a value of 23 billion USD. However, BioNTech anticipates that the healthcare insurance systems of many countries will be capable of shouldering a portion of the expenses for patients.

According to Techspot

Mytour's content is for customer care and travel encouragement only, and we are not responsible.

For errors or inappropriate content, please contact us at: [email protected]